argenx SE Expands Immunology Pipeline with Forte Biosciences Deal
Amsterdam, the Netherlands and Dallas, Texas – July 27, 2026 argenx has entered into a definitive agreement to acquire...
ADC AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Amsterdam, the Netherlands and Dallas, Texas – July 27, 2026 argenx has entered into a definitive agreement to acquire...
WEST PALM BEACH, Fla., and SACRAMENTO, Calif., June 30, 2026 Headlands Research announced the acquisition of Clinical Trials Research...
